Company intelligence / Profile preview

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Ownership: Private
Development stage: Phase 2

Overview

The company was formed as a joint venture to develop ricolinostat in China, with a focus on evaluating the safety and efficacy of ricolinostat in patients with chemotherapy-induced peripheral neuropathy (CIPN).

Therapeutic areas: Neurology
Modalities: Small moleculesHDAC6 inhibitors
Industry: Biotech

Drug pipeline

1 asset

ricolinostat

Phase 2

Indications: Diabetic peripheral neuropathy, Chemotherapy-induced peripheral neuropathy, Charcot-Marie-Tooth disease Type 2

Partnerships

Joint venture between Regenacy Pharmaceuticals and 3E Bioventures Capital

Beyond the preview

Go deeper on Beijing 3E-Regenacy Pharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing 3E-Regenacy Pharmaceuticals Co., Ltd..

Explore the full profile